Regeneron and Sanofi Announce Praluent™ (alirocumab) Marketing Authorization Application has Been Accepted for Review by EMA

Monday, January 12, 2015 1 min read

Key Takeaway: Regeneron and Sanofi Announce Praluent™ (alirocumab) Marketing Authorization Application has Been Accepted for Review by EMA

Full Press Release Details

Regeneron and Sanofi Announce Praluent™ (alirocumab) Marketing Authorization Application has Been Accepted for Review by EMA.